Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases

Key Takeaways

• Single dose suppresses itch and inflammation for 112 days.
• Dose‑dependent inhibition observed at 0.3‑10 mg/kg in primates.
• Improves lung function and reduces asthma airway inflammation.
• Shows favorable preclinical safety across multiple atopic models.
• Phase 1/1b trials began Dec 2025; data due H2 2026.

Pulse Analysis

The atopic disease landscape has been dominated by single‑pathway biologics such as dupilumab, which targets the IL‑4Rα subunit to curb type‑2 inflammation. Zai Lab’s ZL-1503 takes a novel route by simultaneously neutralizing IL‑13, a driver of tissue remodeling, and IL‑31Rα, the primary itch mediator. This dual blockade addresses the itch‑scratch‑inflammation cycle at its core, promising faster symptom relief and potentially higher efficacy for patients who remain refractory to existing therapies.

Preclinical results presented at IMMUNOLOGY2026 reveal that a solitary intravenous infusion of ZL-1503 achieved dose‑dependent suppression of IL‑31‑induced scratching and IL‑13‑driven pSTAT6 signaling for up to 112 days. The antibody also improved lung function in asthma models and mitigated allergic rhinitis and conjunctivitis, indicating broad applicability across IL‑13/IL‑31‑driven conditions. Importantly, the safety profile remained clean across non‑human primate studies, a critical factor for advancing to human trials and for positioning the drug as a less‑frequent dosing option compared with current biologics that require bi‑weekly or monthly administrations.

For Zai Lab, the data bolster a pipeline that already spans oncology, neuroscience and infectious disease, adding a high‑potential immunology asset that could drive near‑term revenue growth. Investors will watch the upcoming Phase 1/1b readouts slated for H2 2026, as positive outcomes could accelerate regulatory pathways and open partnerships with major dermatology and respiratory players. Even if the drug ultimately targets a niche segment, its first‑in‑class mechanism may set a new benchmark for bispecific antibody development in the broader biotech arena.